| Autor: |
da Cunha, D. H. Fernandes, dos Santos, A. M. Nunes, Kopelman, B. I., Areco, K. N., Guinsburg, R., de Araújo Peres, C., Chiba, A. K., Kuwano, S. T., Terzian, C. C. N., Bordin, J. O. |
| Předmět: |
|
| Zdroj: |
Transfusion Medicine; Dec2005, Vol. 15 Issue 6, p467-473, 7p, 3 Charts |
| Abstrakt: |
The goal of this research was to study the safety and the efficacy of transfusing citrate-phosphate-adenine anticoagulant-preservative (CPDA-1) RBC stored for up to 28 days to reduce donor exposures in premature infants. A prospective randomized two-group study was conducted with very low-birth-weight premature infants that received at least one RBC transfusion during hospital stay. Neonates randomly assigned to Group 1 (26 infants) were transfused with CPDA-1 RBC stored for up to 28 days; those assigned to Group 2 (26 infants) received CPDA-1 RBC stored for up to 3 days. Demographic and transfusion-related data were collected. Neonates from both groups showed similar demographics and clinical characteristics. The number of transfusions per infant transfused was 4·4 ± 4·0 in Group 1 and 4·2 ± 3·1 in Group 2, and the number of donors per infant transfused was 1·5 ± 0·8 (Group 1) and 4·3 ± 3·4 (Group 2), P < 0·001. RBC transfusions containing 29·7 ± 18·3 mmol L−1 of potassium (RBC stored for up to 28 days) did not cause clinical or biochemical changes and reduced donor exposures by 70·2%, compared to transfusions containing 19·8 ± 12·3 mmol L−1 of potassium (RBC stored for up to 3 days), P < 0·001. In conclusion, RBC stored for up to 28 days safely reduced donor exposures in premature infants. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
